HTGC

Hercules Capital, Inc. (HTGC) 2024 Annual Report Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2024, for Hercules Capital, Inc., an internally managed, non-diversified Business Development Company (BDC) and Regulated Investment Company (RIC). The Company focuses on providing senior secured loans, primarily "Structured Debt" (debt with equity/warrant features), to high-growth, venture capital-backed technology and life sciences companies. As of December 31, 2024, the Company managed approximately $4.8 billion in assets, including its own portfolio and third-party funds managed by its Adviser Subsidiary.

Key Financial Metrics

Material Changes vs. Prior Period

• Portfolio Growth: The total investment portfolio increased by approximately 12.7% to $3.66 billion, driven by new fundings of $1.81 billion (gross) and accretion of loan discounts/PIK interest.
• Realized Losses: The Company recognized a net realized loss of $31.7 million in 2024, compared to a net realized gain of $8.4 million in 2023. This was primarily due to a $63.1 million write-off of debt investments in Convoy, Inc., Gritstone Bio, Inc., Better Therapeutics, Inc., and Eigen Technologies Ltd., partially offset by gross realized gains of $39.7 million from equity/warrant sales (e.g., Palantir, DoorDash).
• Unrealized Depreciation: Net unrealized depreciation of $31.2 million was recorded in 2024, reversing the $25.0 million appreciation seen in 2023. This reflects valuation adjustments across debt, equity, and warrant holdings.
• Expense Increase: Total net operating expenses rose to $167.8 million from $156.6 million, driven by higher interest costs on debt (weighted average cost of debt increased to 5.0%) and increased employee compensation.
• Portfolio Composition Shift: The "Software" sector grew to 29.5% of the portfolio (from 23.6%), while "Drug Discovery & Development" decreased to 29.5% (from 38.7%). "Healthcare Services, Other" increased significantly to 16.7% (from 9.3%).

Guidance, Outlook, and Risks

Management Commentary: Management maintains a variable distribution policy targeting 90-100% of taxable quarterly income. The Company declared a Q4 2024 distribution of $0.40 per share plus a supplemental distribution of $0.28 per share (to be paid in installments starting Q1 2025). The Company continues to originate new investments, with $297.6 million in non-binding term sheets outstanding as of year-end.

Key Risks and Contingencies:

• Concentration Risk: The portfolio is heavily concentrated in four sectors (Software, Drug Discovery, Healthcare Services, Consumer/Business Services), representing 85.9% of total fair value. Six portfolio companies represented over 5% of net assets each.
• Liquidity and Prepayments: The Company received $922.0 million in early principal repayments in 2024. Reinvestment of these proceeds at lower yields could impact future net investment income.
• Interest Rate Sensitivity: While 97.4% of the debt portfolio is floating rate (providing protection against rate hikes), the Company's cost of debt is also floating. A rise in rates could compress net investment income if asset yields do not adjust as quickly as funding costs.
• Valuation Uncertainty: Approximately 95.5% of assets are Level 3 investments valued in good faith by the Board, introducing subjectivity to the reported NAV.

Investor Verification Checklist

• Verify Write-off Details: Review the specific circumstances and recovery potential regarding the $63.1 million debt write-offs (Convoy, Gritstone, etc.) to assess future credit risk.
• Monitor Reinvestment Yield: Track the yield on new investments funded from the $922 million in early repayments to ensure the portfolio yield does not compress significantly.
• Check Asset Coverage: Confirm the Company maintains the required 150% asset coverage ratio (currently 231.7% excluding SBA) to ensure continued ability to pay dividends and borrow.
• Review Tax Character of Distributions: Verify the tax characterization of the 2024 distributions (Ordinary Income vs. Capital Gains vs. Return of Capital) as reported in the final tax notice, noting the $0.96 per share of undistributed taxable earnings carried forward.
• Assess Sector Exposure: Evaluate the impact of potential regulatory or market downturns in the "Drug Discovery" and "Software" sectors, which comprise nearly 60% of the portfolio.